Docality.com Logo
 
Dr. Steven  Berney  Md image

Dr. Steven Berney Md

3401 N Broad St
Philadelphia PA 19140
215 073-3635
Medical School: State University Of New York At Buffalo School Of Medicine - 1962
Accepts Medicare: Yes
Participates In eRX: No
Participates In PQRS: No
Participates In EHR: No
License #: MD012958E
NPI: 1144217043
Taxonomy Codes:
207RR0500X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Steven Berney is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:96413 Description:Chemo iv infusion 1 hr Average Price:$600.00 Average Price Allowed
By Medicare:
$135.67
HCPCS Code:20610 Description:Drain/inject joint/bursa Average Price:$335.88 Average Price Allowed
By Medicare:
$85.44
HCPCS Code:20605 Description:Drain/inject joint/bursa Average Price:$202.67 Average Price Allowed
By Medicare:
$62.07
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$200.00 Average Price Allowed
By Medicare:
$109.93
HCPCS Code:99232 Description:Subsequent hospital care Average Price:$140.83 Average Price Allowed
By Medicare:
$73.30
HCPCS Code:99213 Description:Office/outpatient visit est Average Price:$129.62 Average Price Allowed
By Medicare:
$74.08
HCPCS Code:99212 Description:Office/outpatient visit est Average Price:$95.00 Average Price Allowed
By Medicare:
$45.09
HCPCS Code:36415 Description:Routine venipuncture Average Price:$20.00 Average Price Allowed
By Medicare:
$3.00
HCPCS Code:J1030 Description:Methylprednisolone 40 MG inj Average Price:$15.00 Average Price Allowed
By Medicare:
$3.40

HCPCS Code Definitions

20605
Arthrocentesis, aspiration and/or injection; intermediate joint or bursa (eg, temporomandibular, acromioclavicular, wrist, elbow or ankle, olecranon bursa)
20610
Arthrocentesis, aspiration and/or injection; major joint or bursa (eg, shoulder, hip, knee joint, subacromial bursa)
96413
Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
99212
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent face-to-face with the patient and/or family.
99213
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
J1030
Injection, methylprednisolone acetate, 40 mg
99232
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is responding inadequately to therapy or has developed a minor complication. Typically, 25 minutes are spent at the bedside and on the patient's hospital floor or unit.

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1669460598
Diagnostic Radiology
234
1154319044
Cardiovascular Disease (Cardiology)
198
1396878344
Rheumatology
149
1841288776
Diagnostic Radiology
139
1629067558
Diagnostic Radiology
114
1194714022
Diagnostic Radiology
98
1558359612
Diagnostic Radiology
87
1154318061
Rheumatology
68
1992793855
Vascular Surgery
62
1083684500
Rheumatology
61
*These referrals represent the top 10 that Dr. Berney has made to other doctors

Publications

Outcomes analysis of Internet-based CME initiatives for diagnosis and treatment of fibromyalgia patients: transition from education to physician behavior to patient health. - Neuropsychiatric disease and treatment
A well designed outcomes research study was performed in which 20 primary care physicians were selected to participate. Each physician had more than 30 fibromyalgia patients in their practice. The study design consisted of four phases. In phase one, physicians undertook a self-assessment of their practice. Phase two of the study involved diagnosis and treatment of a virtual case vignette. The third phase consisted of analysis of the data from phase two and providing feedback from an expert rheumatologist, and the fourth phase was to complete patient report forms for five patients in their practice. The year-long study was completed by 12 physicians and resulted in data on 60 patients. The results of this study provide an insight into how physicians are diagnosing and treating patients with fibromyalgia. In this study, we transition from continuing medical education to physician behavior to patient outcomes.
Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. - Clinical rheumatology
An understanding of the cytokine cascade in a rheumatoid joint has led to the development of new therapeutic options, including drugs targeting tumor necrosis factor-alpha (TNF-alpha). The safety profile of these agents in patients with hepatitis-induced liver disease, however, remains a concern because of risks associated with immune suppression. To examine the effect of three different TNF-alpha antagonists, infliximab, etanercept, and adalimumab, on serum transaminases and hepatitis viral load in patients with rheumatoid arthritis (RA) and concurrent hepatitis B (HBV) or hepatitis C (HCV). Medical records of 11 patients with diagnosis of RA and documented seropositivity for hepatitis B or hepatitis C were retrospectively reviewed for worsening of hepatic inflammation and viral proliferation as measured by a rise in aspartate aminotransferase (AST) or alanine aminotransferase (ALT) and viral load while using these agents. Three patients had RA with concurrent chronic HBV and eight patients had RA with concurrent chronic HCV. Seven patients remained on a single anti-TNF-alpha agent and four patients switched to a second anti-TNF-alpha agent due to treatment failure. Two patients showed a transient elevation in AST and/or ALT from normal, but in all 11 patients, AST and ALT levels were within one time the upper range of normal at the conclusion of the study. No significant increase in viral load was seen except one patient who showed a fourfold increase from baseline. Our case series supports results obtained from previous studies examining the safety of anti-TNF-alpha agents in patients with underlying hepatic disease. Use of these agents in patients with HBV or HCV may be associated with a transient transaminitis but appears to be safe overall. In both groups, frequent monitoring of serum transaminase levels and viral load is essential.
Effects of methotrexate use in a patient with rheumatoid arthritis and multiple sclerosis. - Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
Rheumatoid arthritis (RA) and multiple sclerosis (MS) share similar pathophysiologic processes but coexistence of both diseases in the same patient has rarely been described. We describe the case of a 32 year old woman with rheumatoid arthritis treated with 12.5 mg of methotrexate once a week and 1 mg folic acid who developed paresthesias of her upper and lower extremities. Three years later, she acutely developed 6th nerve palsy, gait imbalance and urinary urgency and a diagnosis of multiple sclerosis was made. The use of methotrexate, though effective in controlling her rheumatoid arthritis, did not influence the development or progression of her multiple sclerosis. Although RA and MS may coexist in the same patient, treatment of one disease may have no influence on the clinical course of the other. Thus, the mechanism by which methotrexate suppresses disease activity in RA but not in MS despite both being T-cell mediated autoimmune diseases requires further investigative studies.
Risk of development of lung cancer is increased in patients with rheumatoid arthritis: a large case control study in US veterans. - The Journal of rheumatology
To investigate the occurrence of lung cancer in patients with rheumatoid arthritis (RA) in the US veteran population. Patients with rheumatic diseases appear to have an increased risk for the development of lymphoproliferative and some solid organ malignancies.We conducted a retrospective case control study using prospectively collected data from the Veterans Integrated Service Networks (VISN) 16 Veteran Affairs (VA) database from 1998 to 2004. We studied the association of RA and lung cancer and analyzed data on 483,721 VA patients. Patients were identified by searching for the diagnoses of RA and lung cancer based on the International Classification of Diseases (ICD) codes. We identified 8768 (1.81%) patients with a diagnosis of RA (ICD code 714.0), 7280 (1.5%) patients with lung cancer (ICD code 162.0), 247 patients with lung cancer and RA, and 7033 patients with lung cancer but no RA. Logistic regression analysis was performed to adjust for age, gender, race, and tobacco and asbestos exposure. Statistical tests were conducted at a 5% level of significance.The diagnosis of RA was determined to have a significant association with lung cancer in this veteran population. Patients with RA are 43% (odds ratio 1.43) more likely to develop lung cancer than patients without RA, when adjusted for covariates.Our study shows a significant positive association between RA and the development of lung cancer in the veteran population. Veterans with RA have an increased incidence of lung cancer when compared to the non-RA population.
Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports. - Clinical rheumatology
Tumor necrosis factor (TNF)-alpha antagonists successfully modulate the pathogenesis of rheumatoid arthritis (RA). However, little is known about the effect of TNF-alpha blockade on the histology of chronic viral hepatitis. We describe the cases of two patients with RA, one with concurrent chronic hepatitis B virus and the other with hepatitis C virus infection who, as part of their evaluation, underwent liver biopsies while undergoing treatment with a TNF-alpha antagonist.
Successful etanercept use in an HIV-positive patient with rheumatoid arthritis. - Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
Limited information exists on treatment of rheumatoid arthritis in a patient with coexisting human immunodeficiency virus (HIV) infection. We report a case of a patient with rheumatoid arthritis who then became HIV positive. His HIV viral load was controlled with antiretroviral therapy, but he continued to have active rheumatoid arthritis despite therapy with hydroxychloroquine, sulfasalazine, and corticosteroids. Because of unremitting rheumatoid disease, we are now treating him with a TNFalpha inhibitor, and his rheumatoid disease activity has decreased from 28 swollen and tender joint count to less than 5.

Map & Directions

3401 N Broad St Philadelphia, PA 19140
View Directions In Google Maps

Nearby Doctors

3401 N Broad St
Philadelphia, PA 19140
215 074-4085
3401 N Broad St
Philadelphia, PA 19140
215 072-2000
3401 N Broad St
Philadelphia, PA 19140
215 072-2000
3401 N Broad St
Philadelphia, PA 19140
215 072-2969
3401 N Broad St
Philadelphia, PA 19140
215 073-3375
3401 N Broad St
Philadelphia, PA 19140
215 075-5435
3401 N Broad St
Philadelphia, PA 19140
215 072-2000
3401 N Broad St
Philadelphia, PA 19140
215 074-4600
3401 N Broad St Parkinson Pavilion Suite 400
Philadelphia, PA 19140
215 075-5080
3401 N Broad St Parkinson Pavilion, Suite 400
Philadelphia, PA 19140
215 075-5080